マーケットレポート詳細

抗生物質：技術および世界市場2027年予測

Antibiotics: Technologies and Global Markets

出版元：BCC Research　 出版元について
発行年：2023年5月
定価 ：定価 Single User License(1名様ライセンス)US$5,500 (米国ドル) /2 to 5 Users License(5名様)$6,600 /Site License $7,920 / Enterprise License $9,504
ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。
ご請求は円換算（お見積り日TTSレート）となります。
納品形態：PDF by Email
当調査レポートは英文150ページになります。
商品コード：BCC460

お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。

【レポート紹介】

抗生物質の世界市場規模は、2022年の404億ドルから今後2027年には496億ドルへと拡大が予測されます。2022年から2027年にかけての同市場規模の平均年成長率は4.2%とレポートは分析しています。
当レポートでは、抗生物質の市場概要、市場ダイナミクス、地域別市場分析、主要企業プロフィールなどを盛り込み、概略以下の構成でお届けいたします。

【レポート構成概要】

◆イントロダクション

・調査目的
・調査対象
・調査手法

◆サマリーと調査ハイライト

◆市場/技術背景

・抗生物質の概要
・抗生物質の分類
・グラム陰性菌/グラム陽性菌の概要
・投与経路
・抗生物質市場の動向

◆市場ダイナミクス

・ドライバー
・障壁
・機会

◆抗生物質市場：製品別

・細胞壁阻害剤
・タンパク質阻害剤
・DNA阻害剤
・その他阻害剤
※市場予測データ掲載-2027年

◆抗生物質市場：投与経路別

・経口抗生物質
・局所抗生物質
・その他投与経路
※市場予測データ掲載-2027年

◆抗生物質市場：地域別

・北米
・欧州
・アジア太平洋
・中南米
・中東アフリカ
※地域別に主要国別の細分化データ掲載
※国地域別に製品別の市場予測データ掲載

◆COVID-19による製薬業界への影響

・短期的影響
・長期的影響

◆臨床開発/パイプライン製品

・気道感染症

◆バリューチェーン分析

・イントロダクション
・中国：微生物脅威の中心

◆規制シナリオ

・FDA/国際規制
・最近の規制改革
・Ketekのケーススタディ

◆競合状況

・市場シェア分析
・合併/コラボレーション/パートナーシップ/買収

◆抗生物質の主要企業プロフィール

・ABBOTT
・F. HOFFMANN-LA ROCHE AG
・GLAXOSMITHKLINE PLC
・JOHNSON & JOHNSON
・MERCK & CO. INC.
・PFIZER INC.
・SANOFI
・VIATRIS INC.

（全150頁）


【レポート詳細目次、データ項目一覧は当ページ下を参照ください】

Table of Contents (英文詳細目次）

Chapter 1 Introduction

Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
What's New in This Update?
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

Overview of Antibiotics

  • Common Side Effects of Antibiotics

Classification of Antibiotics

  • Cell Wall Inhibitors
  • Protein Inhibitors
  • DNA Inhibitors
  • Other Antibiotic Classes
  • Antibiotic Classification, by Source

Overview of Gram-Negative and Gram-Positive Bacteria
Route of Administration
Trends in the Market for Antibiotics

  • New Antibiotic Development
  • Antibiotic Drug Development, Smaller Pharmaceutical Firms
  • Growing Public/Private Partnerships

Chapter 4 Market Dynamics

Market Drivers

  • Growth Driven by Antibiotics
  • Rising Elder Population and Infection Rate
  • Increasing Hospital-acquired Infections
  • Improved Awareness

Market Restraints

  • Antibiotic-resistant Infections
  • Generics
  • Declining R&D Investment
  • Side Effects of Antibiotics

Market Opportunities

  • Market Expansion
  • Novel Antibacterial Agents

Chapter 5 Market Breakdown, by Product

Global Market for Antibiotics by Product

  • Cell Wall Inhibitors
  • Protein Inhibitors
  • DNA Inhibitors
  • Other Types of Inhibitors

Chapter 6 Market Breakdown, by Route of Administration

Global Market for Antibiotics by Route of Administration

  • Oral Antibiotics
  • Topical Antibiotics
  • Other Routes of Administration

Chapter 7 Market Breakdown, by Region

Global Market for Antibiotics by Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

Chapter 8 Impact of COVID-19 on the Pharmaceutical Industry

Short-term Impact

  • Change in Demand
  • Shift of Communication and Promotions to Remote Interactions
  • R&D Changes

Long-term Impact

  • Delayed Approvals for Non-COVID-related Pharmaceutical Products
  • Self-sufficiency in Pharma
  • Pharmaceutical Industry Growth Slowdown
  • Changes in Consumption Trends in Health-related Products

Chapter 9 Clinical Developments and Pipeline Products

Respiratory Tract Infections

Chapter 10 Value Chain Analysis

Introduction
China: Center of Microbial Threat

Chapter 11 Regulatory Scenario

FDA and International Regulation
Recent Regulatory Reforms
Ketek Case Study

Chapter 12 Competitive Landscape

Global Company Market Share Analysis
Mergers, Collaborations, Partnerships and Acquisitions

Chapter 13 Company Profiles

ABBOTT
F. HOFFMANN-LA ROCHE AG
GLAXOSMITHKLINE PLC
JOHNSON & JOHNSON
MERCK & CO. INC.
PFIZER INC.
SANOFI
VIATRIS INC.

Chapter 14 Appendix: Acronyms

List of Tables
Summary Table A : Global Market for Antibiotics, by Product, Through 2027
Summary Table B : Global Market for Antibiotics, by Route of Administration, Through 2027
Table 1 : Major Differences, Gram-Positive and Gram-Negative Organisms
Table 2 : Proportion of Resistant Strains, by WHO Region
Table 3 : Global Market for Antibiotics, by Product, Through 2027
Table 4 : Global Market for Cell Wall Inhibitor, by Product, Through 2027
Table 5 : Global Market for Cell Wall Inhibitors, by Region, Through 2027
Table 6 : Global Market for Protein Inhibitors, by Product, Through 2027
Table 7 : Global Market for Protein Inhibitors, by Region, Through 2025
Table 8 : Global Market for DNA Inhibitors, by Product, Through 2027
Table 9 : Global Market for DNA Inhibitors, by Region, Through 2027
Table 10 : Global Market for Other Types of Inhibitors, by Region, Through 2027
Table 11 : Global Market for Antibiotics, by Route of Administration, Through 2027
Table 12 : Global Market for Antibiotics, by Region, Through 2027
Table 13 : North American Market for Antibiotics, by Product, Through 2027
Table 14 : North American Market for Antibiotics, by Country, Through 2027
Table 15 : European Market for Antibiotics, by Product, Through 2025
Table 16 : European Market for Antibiotics, by Country, Through 2025
Table 17 : Asia-Pacific Market for Antibiotics, by Product, Through 2027
Table 18 : Asia-Pacific Market for Antibiotics, by Country, Through 2027
Table 19 : Latin American Market for Antibiotics, by Product, Through 2027
Table 20 : Latin American Market for Antibiotics, by Country, Through 2025
Table 21 : Middle Eastern and African Market for Antibiotics, by Product, Through 2027
Table 22 : Middle Eastern and African Market for Antibiotics, by Country, Through 2027
Table 23 : Antibiotics and Combinations in Global Clinical Development, Recent Approvals,2023
Table 24 : FDA-approved Antibacterial Drugs, 2018
Table 25 : FDA-Approved Antibacterial Drugs, 2019
Table 26 : Abbott: Antibiotics Product Portfolio
Table 27 : F. Hoffmann-La Roche AG: Antibiotics Product Portfolio
Table 28 : GlaxoSmithKline Plc: Antibiotics Product Portfolio
Table 29 : Johnson & Johnson: Antibiotics Product Portfolio
Table 30 : Merck & Co. Inc.: Antibiotics Product Portfolio
Table 31 : Merck & Co. Inc.: Antibiotic Drug Overview
Table 32 : Pfizer Inc.: Antibiotics Product Portfolio
Table 33 : Sanofi: Antibiotics Product Portfolio
Table 34 : Sanofi S.A.: Antibiotic Drugs Overview
Table 35 : Vitaris Inc.: Antibiotics Product Portfolio
Table 36 : Acronyms Used in this Report

List of Figures
Summary Figure A : Global Market Shares of Antibiotics, by Product, 2021
Summary Figure B : Global Market Shares of Antibiotics, by Route of Administration, 2021
Figure 1 : Types of Antibiotics, by Origin Source
Figure 2 : Share of API Manufacturing Facilities for All Drugs, by Country/Region, Aug. 2019
Figure 3 : Share of Population Aged 65+, by Region, 2019
Figure 4 : Forecasted Share of Population Aged 65+, by Region, 2050
Figure 5 : Increase in Elder Population, 2011 and 2050
Figure 6 : Distribution of Population with Hospital-acquired Infections, U.S., 2020
Figure 7 : Socioeconomic and Political Factors Contributing to Antibiotic Resistance
Figure 8 : Global Market Shares of Antibiotics, by Product, 2021
Figure 9 : Global Market Shares of Cell Wall Inhibitors, by Product, 2021
Figure 10 : Global Market for Cell Wall Inhibitors, by Region, 2021-2027
Figure 11 : Global Market Shares of Protein Inhibitors, by Product, 2021
Figure 12 : Global Market for Protein Inhibitors, by Region, 2019-2027
Figure 13 : Global Market Shares of DNA Inhibitors, by Product, 2019
Figure 14 : Global Market for DNA Inhibitors, by Region, 2019-2027
Figure 15 : Global Market for Other Types of Inhibitors, by Region, 2019-2027
Figure 16 : Global Market Shares of Antibiotics, by Route of Administration, 2021
Figure 17 : Global Market Shares of Antibiotics, by Region, 2021
Figure 18 : North American Market Shares of Antibiotics, by Product, 2021
Figure 19 : North American Market Shares of Cell Wall Inhibitors, by Product, 2021
Figure 20 : North American Market Shares of Protein Inhibitors, by Product, 2021
Figure 21 : North American Market Shares of DNA Inhibitors, by Product, 2021
Figure 22 : North American Market Shares of Antibiotics, by Country, 2022
Figure 23 : U.S. Market for Antibiotics, 2019-2027
Figure 24 : Canadian Market for Antibiotics, 2019-2027
Figure 25 : Mexican Market for Antibiotics, 2019-2027
Figure 26 : European Market Shares of Antibiotics, by Product, 2021
Figure 27 : European Market Shares of Cell Wall Inhibitors, by Product, 2021
Figure 28 : European Market Shares of Protein Inhibitors, by Product, 2021
Figure 29 : European Market Shares of DNA Inhibitors, by Product, 2021
Figure 30 : European Market Shares of Antibiotics, by Country, 2021
Figure 31 : German Market for Antibiotics, 2019-2027
Figure 32 : French Market for Antibiotics, 2019-2027
Figure 33 : U.K. Market for Antibiotics, 2019-2027
Figure 34 : Italian Market for Antibiotics, 2019-2027
Figure 35 : Spanish Market for Antibiotics, 2019-2027
Figure 36 : Rest of European Market for Antibiotics, 2019-2027
Figure 37 : Asia-Pacific Market Shares of Antibiotics, by Product, 2021
Figure 38 : Asia-Pacific Market Shares of Cell Wall Inhibitors, by Product, 2021
Figure 39 : Asia-Pacific Market Shares of Protein Inhibitors, by Product, 2021
Figure 40 : Asia-Pacific Market Shares of DNA Inhibitors, by Product, 2021
Figure 41 : Asia-Pacific Market Shares of Antibiotics, by Country, 2021
Figure 42 : Japanese Market for Antibiotics, 2019-2027
Figure 43 : Chinese Market for Antibiotics, 2019-2027
Figure 44 : Indian Market for Antibiotics, 2019-2027
Figure 45 : Australia and New Zealand Market for Antibiotics, 2019-2027
Figure 46 : Rest of Asia-Pacific Market for Antibiotics, 2019-2027
Figure 47 : Latin American Market Shares of Antibiotics, by Product, 2021
Figure 48 : Latin American Market Shares of Cell Wall Inhibitors, by Product, 2021
Figure 49 : Latin American Market Shares of Protein Inhibitors, by Product, 2021
Figure 50 : Latin American Market Shares of DNA Inhibitors, by Product, 2021
Figure 51 : Latin American Market Shares of Antibiotics, by Country, 2021
Figure 52 : Brazilian Market for Antibiotics, 2019-2027
Figure 53 : Argentinian Market for Antibiotics, 2019-2027
Figure 54 : Rest of Latin American Market for Antibiotics, 2019-2027
Figure 55 : Middle Eastern and African Market Shares of Antibiotics, by Product, 2021
Figure 56 : Middle Eastern and African Market Shares of Cell Wall Inhibitors, by Product, 2021
Figure 57 : Middle Eastern and African Market Shares of Protein Inhibitors, by Product, 2021
Figure 58 : Middle Eastern and African Market Shares of DNA Inhibitors, by Product, 2021
Figure 59 : Middle Eastern and African Market Shares of Antibiotics, by Country, 2021
Figure 60 : GCC Countries’ Market for Antibiotics , 2019-2027
Figure 61 : South African Market for Antibiotics, 2021-2027
Figure 62 : Rest of Middle Eastern and African Market for Antibiotics, 2019-2027
Figure 63 : Impact of COVID-19 on the Pharmaceutical Industry
Figure 64 : Value Chain Analysis
Figure 65 : Global Market Shares of Antibiotics, by Manufacturer, 2021
Figure 66 : Abbott: Annual Revenue, 2019-2021
Figure 67 : Abbott: Revenue Shares, by Country/Region, 2021
Figure 68 : Abbott: Revenue Shares, by Business Unit, 2021
Figure 69 : F. Hoffmann-La Roche AG: Annual Revenue, 2019-2022
Figure 70 : F. Hoffmann-La Roche AG: Revenue Shares in Pharmaceutical Segment, by Country/Region, 2022
Figure 71 : F. Hoffmann-La Roche AG: Revenue Shares, by Business Segment, 2022
Figure 72 : F. Hoffmann-La Roche AG: Revenue Shares, by Therapeutic Segment, 2022
Figure 73 : GlaxoSmithKline Plc: Annual Revenue, 2020-2022
Figure 74 : GlaxoSmithKline Plc: Revenue Shares, by Pharmaceutical, 2022
Figure 75 : GlaxoSmithKline Plc: Revenue Shares, by Product Category, 2022
Figure 76 : GlaxoSmithKline Plc: Revenue Shares, by Region, 2022
Figure 77 : Johnson & Johnson: Annual Revenue, 2019-2021
Figure 78 : Johnson & Johnson: Revenue Shares, by Region, 2021
Figure 79 : Johnson & Johnson: Revenue Shares, by Business Unit, 2021
Figure 80 : Merck & Co. Inc.: Annual Revenue, 2020-2022
Figure 81 : Merck & Co. Inc.: Revenue Shares, by Region, 2019
Figure 82 : Merck & Co. Inc.: Revenue Shares, by Business Unit, 2019
Figure 83 : Pfizer Inc.: Annual Revenue, 2020-2022
Figure 84 : Pfizer Inc.: Revenue Shares, by Region, 2022
Figure 85 : Pfizer Inc.: Revenue Shares, by Country, 2022
Figure 86 : Pfizer Inc.: Revenue Shares, by Business Segment, 2022
Figure 87 : Sanofi: Annual Revenue, 2020-2022
Figure 88 : Sanofi: Revenue Shares, by Region/Country, 2022
Figure 89 : Sanofi: Revenue Shares, by Business Segment, 2022
Figure 90 : Viatris Inc.: Annual Revenue, 2020-2022
Figure 91 : Vitaris Inc.: Revenue Shares, by Region, 2022
Figure 92 : Vitaris Inc.: Revenue Shares, by Business Unit, 2022


△ 一番上に戻る